Before your body produces specific antibodies against a new invader, a powerful defense system is already hard at work. Meet the complement system— one of the immune system’s fastest and most sophisticated weapons. This ancient cascade of proteins can detect, tag, and destroy pathogens within minutes, while also bridging innate and adaptive immunity.

Imagine the blueprint for a complex building. It contains every instruction needed to construct it, maintain it, and adapt it over time. In biology, DNA is that blueprint. It is the master plan carried within every cell, dictating how a cell should grow, function, and divide.

But what happens when that blueprint gets torn, stained, or smudged? This is the reality at the microscopic level, and it is a constant threat to our health. Understanding how cells protect and repair their genetic blueprint is one of the most critical areas of modern life science research.

Bioss is excited to announce the 2026 Bioss Travel Grant, created to help support researchers attending scientific conferences and sharing their work with the broader research community.

From major meetings like AACR, AAI, and SfN to other antibody-related scientific conferences, Bioss is proud to support researchers as they present discoveries, build collaborations, and engage with their scientific peers.

From cancer studies to neurodevelopment, from infectious disease models to regenerative medicine, organoids are emerging as a vital bridge between fundamental research and clinical applications.

A scientific perspective vividly describes proteins as locks and small-molecule activators or inhibitors as perfectly matched keys— they insert, turn, or jam the lock, thereby controlling the entire machinery of life. This metaphor, rooted in the classic "lock-and-key model" proposed by Emil Fischer in 1894, continues to gain new vitality in modern drug discovery and biology.

Research into NiV and Hendra virus is crucial for decoding infection mechanisms, improving diagnostics, and accelerating vaccine progress. To support these efforts, Bioss has launched a new series of high-quality recombinant protein products tailored to Nipah and Hendra viruses.